'Cell therapy without cells': Capstan raises $175M to test in vivo CAR-T

Kyle LaHucik

Senior Reporter

Laura Shawver pictures a world 10 years from now where cell therapies are replaced by in vivo CAR-T products. The goal is a cheaper-to-produce, less …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Cell therapy without cells': Capstan raises $175M to test in vivo CAR-T

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Novo Nordisk partners with Broad Institute spinout Photys after the startup's layoffs

Exclusive: Insitro makes headway on the harder road, discovering new ALS drug target

SiteOne Therapeutics, a pain biotech that's partnered with Vertex, nabs $100M

Aurion’s eye cell therapy improves vision in small study, plots Phase 3 trial

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)

'Cell ther­a­py with­out cell­s': Cap­stan rais­es $175M to test in vi­vo CAR-T

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

'Cell therapy without cells': Capstan raises $175M to test in vivo CAR-T

Novo Nordisk partners with Broad Institute spinout Photys after the startup's layoffs

Exclusive: Insitro makes headway on the harder road, discovering new ALS drug target

SiteOne Therapeutics, a pain biotech that's partnered with Vertex, nabs $100M

Aurion’s eye cell therapy improves vision in small study, plots Phase 3 trial

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)